These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36698135)

  • 1. High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients.
    Sejdic A; Frische A; Jørgensen CS; Rasmussen LD; Trebbien R; Dungu A; Holler JG; Ostrowski SR; Eriksson R; Søborg C; Nielsen TL; Fischer TK; Lindegaard B; Franck KT; Harboe ZB
    Virol J; 2023 Jan; 20(1):14. PubMed ID: 36698135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China.
    Wu F; Liu M; Wang A; Lu L; Wang Q; Gu C; Chen J; Wu Y; Xia S; Ling Y; Zhang Y; Xun J; Zhang R; Xie Y; Jiang S; Zhu T; Lu H; Wen Y; Huang J
    JAMA Intern Med; 2020 Oct; 180(10):1356-1362. PubMed ID: 32808970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
    Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
    Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses.
    Glans H; Gredmark-Russ S; Olausson M; Falck-Jones S; Varnaite R; Christ W; Maleki KT; Karlberg ML; Broddesson S; Falck-Jones R; Bell M; Johansson N; Färnert A; Smed-Sörensen A; Klingström J; Bråve A
    BMC Infect Dis; 2021 May; 21(1):494. PubMed ID: 34044758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study.
    Karuna S; Li SS; Grant S; Walsh SR; Frank I; Casapia M; Trahey M; Hyrien O; Fisher L; Miner MD; Randhawa AK; Polakowski L; Kublin JG; Corey L; Montefiori D;
    PLoS Med; 2021 Dec; 18(12):e1003868. PubMed ID: 34871308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing Antibody Responses to SARS-CoV-2 in Korean Patients Who Have Recovered from COVID-19.
    Kim YJ; Bae JY; Bae S; Hwang S; Kwon KT; Chang HH; Lee WK; Cui C; Lee GE; Kim SW; Park MS
    Yonsei Med J; 2021 Jul; 62(7):584-592. PubMed ID: 34164955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
    Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
    J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
    To KK; Tsang OT; Leung WS; Tam AR; Wu TC; Lung DC; Yip CC; Cai JP; Chan JM; Chik TS; Lau DP; Choi CY; Chen LL; Chan WM; Chan KH; Ip JD; Ng AC; Poon RW; Luo CT; Cheng VC; Chan JF; Hung IF; Chen Z; Chen H; Yuen KY
    Lancet Infect Dis; 2020 May; 20(5):565-574. PubMed ID: 32213337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity.
    Stankiewicz Karita HC; Dong TQ; Johnston C; Neuzil KM; Paasche-Orlow MK; Kissinger PJ; Bershteyn A; Thorpe LE; Deming M; Kottkamp A; Laufer M; Landovitz RJ; Luk A; Hoffman R; Roychoudhury P; Magaret CA; Greninger AL; Huang ML; Jerome KR; Wener M; Celum C; Chu HY; Baeten JM; Wald A; Barnabas RV; Brown ER
    JAMA Netw Open; 2022 Jan; 5(1):e2142796. PubMed ID: 35006245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
    Wang K; Long QX; Deng HJ; Hu J; Gao QZ; Zhang GJ; He CL; Huang LY; Hu JL; Chen J; Tang N; Huang AL
    Clin Infect Dis; 2021 Aug; 73(3):e531-e539. PubMed ID: 32745196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High neutralizing antibody titer in intensive care unit patients with COVID-19.
    Liu L; To KK; Chan KH; Wong YC; Zhou R; Kwan KY; Fong CH; Chen LL; Choi CY; Lu L; Tsang OT; Leung WS; To WK; Hung IF; Yuen KY; Chen Z
    Emerg Microbes Infect; 2020 Dec; 9(1):1664-1670. PubMed ID: 32618497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia.
    Chen W; Zhang J; Qin X; Wang W; Xu M; Wang LF; Xu C; Tang S; Liu P; Zhang L; Liu X; Zhang Y; Yi C; Hu Z; Yi Y
    Biomed Pharmacother; 2020 Oct; 130():110629. PubMed ID: 33406577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal neutralizing antibody responses after SARS-CoV-2 infection: A convalescent cohort study in Taiwan.
    Huang YF; Hsu FC; Wu JJ; Lin YL; Liu MT; Yang CH; Kuo HS; Chen YJ; Cheng CY; Lin HH; Liao CC; Chang CS; Liang JJ; Cheng WY; Huang JC; Chen CP; Cheng SH; Lin YC; Yang SH; Chou YJ
    J Microbiol Immunol Infect; 2023 Jun; 56(3):506-515. PubMed ID: 36967265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates.
    Mollan KR; Eron JJ; Krajewski TJ; Painter W; Duke ER; Morse CG; Goecker EA; Premkumar L; Wolfe CR; Szewczyk LJ; Alabanza PL; Loftis AJ; Degli-Angeli EJ; Brown AJ; Dragavon JA; Won JJ; Keys J; Hudgens MG; Fang L; Wohl DA; Cohen MS; Baric RS; Coombs RW; Sheahan TP; Fischer WA
    Clin Infect Dis; 2022 Aug; 75(1):e1028-e1036. PubMed ID: 35022711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between SARS-CoV-2 antibody titer and the severity of COVID-19.
    Park JH; Cha MJ; Choi H; Kim MC; Chung JW; Lee KS; Jeong DG; Baek MS; Kim WY; Lim Y; Yoon SW; Choi SH
    J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 1):1094-1100. PubMed ID: 35570185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early and High SARS-CoV-2 Neutralizing Antibodies Are Associated with Severity in COVID-19 Patients from India.
    Shrivastava S; Palkar S; Shah J; Rane P; Lalwani S; Mishra AC; Arankalle VA
    Am J Trop Med Hyg; 2021 Jun; 105(2):401-406. PubMed ID: 34138748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Puenpa J; Wanlapakorn N; Chirathaworn C; Sudhinaraset N; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Ayuthaya TPN; Brukesawan C; Intharasongkroh D; Chaiwanichsiri D; Issarasongkhram M; Kitphati R; Mungaomklang A; Thitithanyanont A; Nagavajara P; Poovorawan Y
    PLoS One; 2022; 17(4):e0267102. PubMed ID: 35446889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
    Bartelt LA; Markmann AJ; Nelson B; Keys J; Root H; Henderson HI; Kuruc J; Baker C; Bhowmik DR; Hou YJ; Premkumar L; Cornaby C; Schmitz JL; Weiss S; Park Y; Baric R; de Silva AM; Lachiewicz A; Napravnik S; van Duin D; Margolis DM
    mBio; 2022 Oct; 13(5):e0175122. PubMed ID: 36135380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.